OriCol™ is a minimally invasive, single use device developed specifically to collect and harness the rectal mucus specimen for improved gastrointestinal disease diagnostics, screening and monitoring. Current in vitro diagnostic methods such as stool or blood tests are limited in accuracy, which means too many cases of CRC are detected late. OriCol™ addresses these challenges by collecting a mucosal sample from the rectum where shed or exfoliated upstream material can be found.
Rectal mucus contains the cells and molecular signals shed from the lining of the entire colon, providing a far more direct and informative sample than blood or stool. This makes it uniquely suited for detecting the earliest signs of CRC and advanced adenomas.
Our research demonstrates that mucosal sampling delivers breakthrough accuracy, offering a clear diagnostic advantage while avoiding the discomfort, complexity, risk and cost of colonoscopy and the low uptake and poor performance associated with other in vitro testing methods.
By replacing unreliable stool sampling tests and reducing reliance on invasive procedures, OriCol™ makes CRC diagnostics and screening faster, safer, and more acceptable for patients. In doing so, it offers a powerful new pathway for earlier detection, when colorectal cancer is most treatable, and a more efficient tool for clinicians working to reduce the burden of this growing disease.
